NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
Incyte Corporation
Enliven Therapeutics
Terns, Inc.
Enliven Therapeutics
Ascentage Pharma Group Inc.
Il-Yang Pharm. Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.